IP Library Granted Patent US 9,040,535
Granted Patent B2
US 9,040,535 · App. 14/047,463 · Granted May 26, 2015

Crystalline molecular comlpexes of tadalafil

Inventors: Mazen Hanna (Lutz, FL); Ning Shan (Tampa, FL); Miranda L. Cheney (Tampa, FL); David R. Weyna (Tampa, FL)
Assignee: THAR PHARMACEUTICALS, INC.
C07D471/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,535
App. No.
14/047,463
Granted
May 26, 2015
Kind
B2
Abstract

Crystalline molecular complexes of tadalafil are disclosed. The crystalline molecular complexes include those of tadalafil and oxalic acid, tadalafil and 4-hydroxybenzoic acid, tadalafil and 3-phenylpropanoic acid, tadalafil and malonic acid, tadalafil and methylparaben, and tadalafil and propylparaben. Pharmaceutical compositions containing the crystalline molecular complexes are also disclosed.

Claims (14)

1. A crystalline molecular complex of tadalafil comprising tadalafil and a propylparaben co-former.

2. A crystalline molecular complex of tadalafil and propylparaben according to claim 1 where the molar ratio of the tadalafil and the propylparaben in the molecular complex is 1:1.

3. A crystalline molecular complex of tadalafil and propylparaben according to claim 1 , wherein the molecular complex is characterized by at least one of the following:

an X-ray powder diffractogram in accordance with FIG. 11 ; or

a Fourier transform infrared spectrum in accordance with FIG. 12 .

4. A crystalline molecular complex of tadalafil and propylparaben of claim 1 , wherein the molecular complex is characterized by: an X-ray powder diffractogram having peaks at 5.2, 10.5, 15.3, 18.7, 20.6, 22.0, and 24.5 °2θ±0.2 °2θ; an infrared spectrum having peaks at 747, 1098, 1271, 1433, 1645, 1700, and 3338 cm −1 ±cm −1 ; or both.

5. A pharmaceutical composition comprising a crystalline molecular complex of tadalafil and propylparaben of claim 4 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising a crystalline molecular complex of tadalafil and propylparaben of claim 1 and a pharmaceutically acceptable carrier.

7. A method for making a crystalline molecular complex of tadalafil and propylparaben according to claim 1 , comprising the steps of:

grinding tadalafil and propylparaben; and

adding acetonitrile to the ground tadalafil and propylparaben.

8. A method for making a crystalline molecular complex of tadalafil and propylparaben according to claim 1 , comprising the steps of:

slurrying tadalafil, propylparaben, and acetonitrile; and

drying the slurried tadalafil, propylparaben, and acetonitrile.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2019
From: GRUNENTHAL GMBH
To: THAR PHARMA, LLC
Reel/Frame 050762/0370 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2017
From: THAR PHARMACEUTICALS, INC.
To: GRUNENTHAL GMBH
Reel/Frame 041224/0125 →
Continuity (3)
Division 13203297
Provisional Application 61208624 · Feb 26, 2009
Related Publication 20140100233A1 · Apr 10, 2014